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To the Editor: Tran and colleagues note that thousands of patients per year in the United States could be eligible for T-cell-based immunotherapy targeting KRAS G12D. We agree. In our National Institutes of Health-funded, populationbased study, we have characterized 4346 colorectal adenocarcinomas since 1998. 1 To date, the prevalence of KRAS mutations is 1441 of 4346 (33.2%), with 37.9% of the KRAS-positive tumors harboring G12D mutations. HLA typing available for 3734 patients shows that 687 (18.4%) have at least one copy of HLA-C*08:02. We found that 85 of 3734 patients (2.3%) with colorectal cancer share the same HLA type and KRAS mutation as described by Tran et al. We have also sequenced the T-cell receptor (TCR) beta chain of tumor-infiltrating lymphocytes to characterize the adaptive immune response in 295 tumors so far, in addition to expert pathological assessment. 2 We detected 6338 shared TCR-β sequences among 2 or more patients, including 5 TCR-β sequences uniquely shared among patients with tumors positive for KRAS G12D and HLA-C*08:02 and 7 TCR-β sequences also shared by patients with KRAS G12D and HLA-C*08:02 e11 (2) and other combinations of KRAS mutations and HLA ( Fig. 1 ). 
The authors reply: The data cited by Rech and Vonderheide in their letter are not consistent with the frequency of HLA-C*08:02 and of the KRAS G12D mutation in the U.S. population. The frequencies of the KRAS G12D mutation are highest in pancreatic, colorectal, and lung adenocarcinomas, being present in approximately 40%, 12%, and 4% of each of these tumor types, respectively. 1 There were approximately 373,000 estimat-ed new cases and 249,000 deaths in the United States in 2016 due to these cancers, 2 and the frequency of HLA-C*08:02 is approximately 8% in U.S. whites and blacks. 3 Therefore, the number of cases and deaths in the United States in 2016 in patients bearing these tumor types expressing the KRAS G12D mutation and HLA-C*08:02 are estimated to be approximately 3300 and 2300, respectively. Our colleagues in the Surgery Branch of the National Cancer Institute (NCI) have also identified T-cell receptors that target KRAS G12Dmutated and KRAS G12V-mutated epitopes in the context of HLA-A*11:01, 4 an HLA class I allele expressed in approximately 14% of whites, which may enable KRAS to be targeted in a larger number of patients.
Furthermore, of the 61 gastrointestinal tract tumors analyzed by whole-exome sequencing in the NCI Surgery Branch, 15 expressed the KRAS G12D mutation, 6 expressed HLA-C*08:02, and 2 expressed the KRAS G12D mutation plus HLA-C*08:02 (Table 1) . These results are similar to those observed in the population studies described above.
The article by Rooney et al. that is cited by Rech and Vonderheide provided evidence for an association between "established" gene signatures that relied on measurement of "local immune infiltrates," as determined by evaluation of granzyme A and perforin expression, and the num- Non-small-cell lung 0/9 1/9 (11) 0/9 Table 1 . Prevalence of KRAS G12D Mutation and HLA-C*08:02 among Patients Evaluated in the Surgery Branch of the National Cancer Institute.
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